These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18535019)

  • 1. Fatigue, depression and progression in multiple sclerosis.
    Koch M; Uyttenboogaart M; van Harten A; Heerings M; De Keyser J
    Mult Scler; 2008 Jul; 14(6):815-22. PubMed ID: 18535019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with the risk of secondary progression in multiple sclerosis.
    Koch M; Uyttenboogaart M; van Harten A; De Keyser J
    Mult Scler; 2008 Jul; 14(6):799-803. PubMed ID: 18573840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality.
    Lobentanz IS; Asenbaum S; Vass K; Sauter C; Klösch G; Kollegger H; Kristoferitsch W; Zeitlhofer J
    Acta Neurol Scand; 2004 Jul; 110(1):6-13. PubMed ID: 15180801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.
    Kobelt G; Texier-Richard B; Lindgren P
    Mult Scler; 2009 Jun; 15(6):741-51. PubMed ID: 19383645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Social anxiety in a multiple sclerosis clinic population.
    Poder K; Ghatavi K; Fisk JD; Campbell TL; Kisely S; Sarty I; Stadnyk K; Bhan V
    Mult Scler; 2009 Mar; 15(3):393-8. PubMed ID: 19028833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.
    Sayao AL; Bueno AM; Devonshire V; Tremlett H;
    Mult Scler; 2011 Nov; 17(11):1375-83. PubMed ID: 21677023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
    Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
    Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression in familial and nonfamilial MS.
    Koch M; Uyttenboogaart M; Heerings M; Heersema D; Mostert J; De Keyser J
    Mult Scler; 2008 Apr; 14(3):300-6. PubMed ID: 18208881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
    Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of birth and disease progression in multiple sclerosis.
    Koch M; De Keyser J; Tremlett H
    Mult Scler; 2008 Jul; 14(6):793-8. PubMed ID: 18573829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothalamic involvement assessed by T1 relaxation time in patients with relapsing-remitting multiple sclerosis.
    Zellini F; Niepel G; Tench CR; Constantinescu CS
    Mult Scler; 2009 Dec; 15(12):1442-9. PubMed ID: 19995847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis.
    Morrow SA; Weinstock-Guttman B; Munschauer FE; Hojnacki D; Benedict RH
    Mult Scler; 2009 Aug; 15(8):998-1005. PubMed ID: 19667024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cigarette smoking and progression in multiple sclerosis.
    Koch M; van Harten A; Uyttenboogaart M; De Keyser J
    Neurology; 2007 Oct; 69(15):1515-20. PubMed ID: 17923613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alexithymia in multiple sclerosis: relationship with fatigue and depression.
    Bodini B; Mandarelli G; Tomassini V; Tarsitani L; Pestalozza I; Gasperini C; Lenzi GL; Pancheri P; Pozzilli C
    Acta Neurol Scand; 2008 Jul; 118(1):18-23. PubMed ID: 18162056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.